US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Bolt Biotherapeutics, Inc. - Common Stock (NQ:BOLT)

3.450 -0.060 (-1.71%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bolt Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Participate in September Investor Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Looking Into Bolt Biotherapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
News headline image
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023 ↗
 
Via Benzinga
News headline image
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials 
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies ↗
 
Via Benzinga
News headline image
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Present at February Investor Conferences
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022 ↗
  
Via Benzinga
News headline image
SVB Leerink Cuts Price Target On This Stock By 50%, Also Check Out Some Other Major PT Changes ↗
SVB Leerink cut the price target on Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) from $8 to $4. SVB Leerink analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Bolt... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million. 
Via Benzinga
News headline image
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday ↗
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Bolt Biotherapeutics's Return On Capital Employed Overview ↗
Bolt Biotherapeutics (NASDAQ:BOLT) brought in sales totaling $508.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 16.08%, resulting in a loss of $27.16... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Soleno Therapeutics (NASDAQ:SLNO) shares rose 15.7% to $0.37 during Monday's pre-market session. The market value of their outstanding shares is at $29.5... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >